Johnson & Johnson (JNJ.MX)

Mexico - Mexico Delayed Price. Currency in MXN
2,276.470.00 (0.00%)
At close: 2:00 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close2,276.47
Bid2,276.47 x 400000
Ask0.00 x 400000
Day's Range2,276.47 - 2,290.00
52wk Range1,550.01 - 2,363.00
1y Target EstN/A
Market Cap6.36T
P/E Ratio (ttm)424.24
Avg Vol (3m)1,911
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters8 hours ago

    J&J psoriasis drug tops placebo, Humira in late stage study

    An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. More than 73 percent of patients who received guselkumab experienced near complete skin clearance compared with 2.9 percent those who received a placebo. In the Humira group, nearly 50 percent of patients saw near complete skin clearance.

  • Bloomberg8 hours ago

    J&J’s Skin Drug Beats Humira in Final-Stage Psoriasis Study

    Johnson & Johnson’s experimental drug for psoriasis hit its main goals and outperformed a rival in a final-stage study, positioning the company to expand its arsenal of immune-disease treatments.

  • Reuters9 hours ago

    Novartis psoriasis drug maintains efficacy after 4 years - study

    Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.